Sutro Biopharma Inc STRO

NAS: STRO | ISIN: US8693671021   31/05/2024
4,225 USD (-2,42%)
(-2,42%)   31/05/2024

28 juni 2022 · Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs) · Persbericht

29 april 2022 · Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

8 april 2022 · Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022 · Persbericht

5 april 2022 · Sutro Biopharma to Present at the 21st Annual Needham Virtual Healthcare Conference · Persbericht

30 maart 2022 · Sutro Biopharma Presented on Advances in Novel Immunostimulatory Antibody-Drug Conjugate Modality at the 12th Annual World ADC · Persbericht

3 maart 2022 · Sutro Biopharma to Participate in the Cowen 42nd Annual Healthcare Conference · Persbericht

28 februari 2022 · Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones · Persbericht

6 januari 2022 · Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference · Persbericht

5 januari 2022 · Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer · Persbericht

13 december 2021 · Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021 · Persbericht

22 november 2021 · Sutro Biopharma to Participate in Two Upcoming Investor Conferences · Persbericht

17 november 2021 · Sutro Biopharma Announces Appointment of Heidi Hunter to Board of Directors · Persbericht

10 november 2021 · Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones · Persbericht

2 november 2021 · Sutro Biopharma to Participate in Three Upcoming Investor Conferences · Persbericht

12 oktober 2021 · Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China · Persbericht

30 september 2021 · Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck · Persbericht

17 september 2021 · Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

16 september 2021 · Sutro Biopharma Announces Expansion of Leadership Team · Persbericht

1 september 2021 · Sutro Biopharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference · Persbericht

18 augustus 2021 · Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer · Persbericht

Mijn selecties